Market capitalization | $12.51m |
Enterprise Value | $21.53m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.38 |
P/S ratio (TTM) P/S ratio | 4.87 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -9.68% |
Revenue (TTM) Revenue | $2.57m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
1 Analyst has issued a forecast HCW Biologics Inc:
1 Analyst has issued a forecast HCW Biologics Inc:
Dec '24 |
+/-
%
|
||
Revenue | 2.57 2.57 |
10%
10%
|
|
Gross Profit | -0.22 -0.22 |
61%
61%
|
|
EBITDA | -16 -16 |
37%
37%
|
EBIT (Operating Income) EBIT | -17 -17 |
35%
35%
|
Net Profit | -30 -30 |
20%
20%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HCW Biologics, Inc. operates as a holding company which engages in the research and development of immunotherapies. It focuses on cancer and aging-associated diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.
Head office | United States |
CEO | Hing Wong |
Employees | 36 |
Founded | 2018 |
Website | www.hcwbiologics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.